Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,142.00
(
0.53%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.67
(
2.41%
)
Bitcoin
74,725.27
(
-0.16%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: masterlongevity post# 81559

Tuesday, 07/28/2009 5:03:52 PM

Tuesday, July 28, 2009 5:03:52 PM

Post# of 257253
MS Drugs: 2Q09 US Market Share 
 
         Sales Market 
           $M  Share  
 Copaxone 438   38% 
 Avonex   366   32% 
 Rebif    198   17% 
 Tysabri  125   11% 
 Other     22    2% 
 =====  =====  ==== 
 Total  1,149  100%
Copaxone, Avonex, and Tysabri sales are as reported
by Teva and Biogen Idec; Rebif sales are estimated
from Merck KGaA and PFE financial statements.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now